FATE News and Press, Fate Therapeutics Inc. From 11/10/22

Summary NKTX came out with strong data in heavily pretreated AML patients in April. Data was at least as good as Fate's data, which is valued nearly 4x higher. Lack of near-term catalysts and a secondary is keeping the stock down. Nkarta ( NKTX ) is a company tha...

Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical Solid Tumor Models Fate and ONO to Jointly Develop and Commercialize FT825/ONO-8250 in U.S. and Europe with ONO having Exclusive Rig...

Fate Therapeutics, Inc. (FATE) Q3 2022 Earnings Conference Call November 03, 2022 05:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & Development Officer ...

Fate Therapeutics press release ( NASDAQ: FATE ): Q3 GAAP EPS of -$0.86 beats by $0.04 . Revenue of $14.98M (+5.3% Y/Y) misses by $0.51M . Cash, cash equivalents and investments as of September 30, 2022 were $519.1 million. For further details see: Fa...

FT596+R Enrollment Ongoing in Three-dose Escalation Cohort for R/R BCL; Activating Community Sites for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL Positive Feedback Received from FDA under FT516 RMAT Designation for Derivation of Clonal Engineer...

Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819 CD19-targeted CAR T-cell Product Candidate for B-cell Lymphoma Preclinical Data of FT555 GPRC5D-targeted CAR NK Cell Collaboration Candidat...

SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cance...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

Summary Due to an extended downtrend in Athersys stock price due largely to a declining cash position, Athersys currently trades at a market cap near $24 million. The current valuation is miniscule when compared to valuations of other stem cell companies, especially when consideri...

SAN DIEGO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present clinical and preclinica...